Research programme: cancer immunotherapies - Cancer Research UK/LifeArc/Ono Pharma
Latest Information Update: 28 Apr 2023
At a glance
- Originator Cancer Research UK; LifeArc
- Class Antibodies; Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for research development in Cancer in Japan
- 28 Apr 2023 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Mar 2019 Cancer Research UK, LifeArc and Ono Pharma enter into a research collaboration to discover and develop cancer therapeutics